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Arteritic anterior ischemic optic neuropathy (AAION), also known as giant cell arteritis, is caused by an ischemia 
of the posterior ciliary arteries and/or the ophthalmic artery. 
The ischemia is due to a granulomatous vasculitis of the vessel 
walls. Therapy is immediate intervention with systemic ster-
oids, especially to protect against vision loss in the other eye. 
Other retinal signs of ischemia may also be present (1). 
Prostaglandin E1 (PGE1) is a potent vasodilator of the micro-
circulation. Intravenous (IV) PGE1 has been successfully used 
to treat seven of eight cases of non-AAION, three cases of 
chronic ischemia in high myopia and a branch retinal arterial 
occlusion (2-4). It has also been shown to improve ocular 
blood flow in patients with decreased flow in the presence of 
peripheral vascular disease and diabetes (5). Because AAION 
is due to ischemia caused by inflammation, the use of a potent 
vasodilator of the microcirculation, together with systemic 
steroids, may help in its treatment. 
The current report presents two patients with AAION who 
were treated with IV steroids and IV PGE1.
case presentations
case 1
In December 2006, a 75-year-old white woman presented to the 
emergency room at the Ophthalmic Hospital (Rome, Italy) with 
a sudden loss of vision in her right eye (OD). She had a 
two-month history of general muscle pain, jaw claudication and 
right-sided temporal pain. She was being treated for diabetes and 
hypertension, and underwent a complete dilated eye examina-
tion. Her best corrected visual acuity (BCVA) in the OD, using 
the Snellen visual acuity chart, was 4/50 (less than 20/200), 
recognizing only one of two letters with a –0.75 sphere. Her 
BCVA in the left eye (OS) was 5/10 (20/40) with a –1.50 sphere. 
Her intraocular pressures were normal and she had mild cata-
racts. The fundus examination revealed optic disc edema (ODE) 
in the OD, a normal- appearing optic nerve head (ONH) in the 
OS and mild retinal pigmentary epithelial changes in the macula 
of both eyes. Her blood work revealed an erythrocyte sedimenta-
tion rate (ESR) of 125 mm/h (the normal value is less than 
20 mm/h for the Westergren test), a glucose level of 250 mmol/L 
and a C-reactive protein (CRP) level of 14.87 mg/L (the normal 
value is less than 5 mg/L). She was then seen by an internist for 
a medical examination, who made the diagnosis of AAION. She 
refused a temporal artery biopsy. Once the diagnosis was made 
and after explaining the experimental nature of the treatment, 
written consent was obtained and the patient was rapidly given 
20 mg of IV 6-methylprednisolone. This was followed by 80 µg 
of PGE1 with 2 mEq of potassium in 250 mL of IV physiological 
solution (NaCl 0.9%) over 3 h. Normally, a higher dose of IV 
6-methylprednisolone would have been used as a starting dose 
but, due to the patient’s diabetes, the internist used only 20 mg. 
Her pulse and systemic blood pressure were monitored every 
15 min. On the following morning, the same treatment was 
repeated first with 20 mg of IV  6-methylprednisolone immedi-
ately followed by 80 µg of PGE1 with 2 mEq of potassium by IV 
infusion over 3 h. The next day, 48 h after the first IV infusion, 
the vision in the OD had improved to 5/10 (20/40) with a 
reduction in the ODE. The OS was unchanged. After one week, 
the visual acuity was unchanged and the optic disc in the OD 
was pale without edema. At six months, the BCVA, using the 
Snellen chart, in the OD improved to 6/10 (20/35) and was 
unchanged in the OS. After the first two IV infusions of 80 µg 
of PGE1, no further PGE1 treatments were given. She was fol-
lowed by the internist. After the first two days of IV 
 6-methylprednisolone, she was started on 25 mg of prednisone 
once daily for three days followed by 12.5 mg once daily for 
45 days. The steroids were gradually reduced to 5 mg a day and 
stopped. After one week of treatment, the ESR was 72 mm/h 
and the CRP level was 1.42 mg/L (normal was lower than 
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Arteritic anterior ischemic optic neuropathy (AAION) is an acute 
ischemia of the posterior ciliary arteries and/or ophthalmic artery due to 
inflammation. Therapy is immediate intervention with systemic steroids, 
especially to protect against vision loss in the other eye. The addition of a 
potent vasodilator to the steroids could help restore ocular blood flow and 
improve visual acuity. The objective of the current report was to present 
the use of prostaglandin E1 (PGE1) – a powerful vasodilator of the 
microcirculation – in the treatment of AAION. Two patients with 
AAION were treated with intravenous steroids and PGE1. The visual acu-
ity improved from 4/50 (less than 20/200) to 6/10 (20/35) in one patient 
and from 1/50 (20/400) to 1/10 (20/200) in the second patient. The visual 
fields in both patients maintained small central islands of vision. No com-
plications due to the use of PGE1 were seen. Intravenous PGE1 should be 
considered in addition to steroids in cases of AAION to immediately 
restore blood flow to the optic nerve and improve visual acuity while the 
steroids reduce the inflammation.
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1 mg/L). This second CRP level was measured in a different 
laboratory with different normal values. After two weeks of 
treatment, the ESR was 12 mm/h and the CRP level was 
0.95 mg/L (again, the normal CRP level was lower than 
1 mg/L). Her medical complaints of general muscle pain, jaw 
claudication and right-sided temporal pain disappeared. Octopus 
(Haag-Streit International, Switzerland) visual fields (VFs) 
were measured six and 12 months after treatment, and were 
essentially the same. The mean deviation (MD) was –22 dB 
with a dense peripheral scotoma of 360° and a small island of 
central vision extending nasally.
case 2 
In January 2007, an 84-year-old diabetic white woman pre-
sented to the emergency room at the Ophthalmic Hospital 
with a sudden loss of vision in the OS. She had a one-month 
history of jaw claudication and left-sided temporal pain. Her 
BCVA using the Snellen visual acuity chart was 3/10 (20/70) 
in the OD and 1/50 (20/400) in the OS. Her intraocular pres-
sures were normal. She had mild cataracts and mild macular 
degeneration in both eyes. The ONH was pale in the OD and 
there was ODE in the OS. Her blood work revealed an ESR of 
82 mm/h and a CRP level of 8.7 mg/L (normal was lower than 
5 mg/L). After a medical examination by an internist, a diag-
nosis of AAION was made. A temporal artery biopsy was not 
obtained. After explaining the experimental nature of the 
treatment, written consent was obtained and the patient 
rapidly received 40 mg of IV  6-methylprednisolone followed by 
80 µg of PGE1 with 2 mEq of potassium by IV infusion as 
described for the first patient. The same treatment was repeated 
on the second day. On the third day, she was started on 25 mg 
of predisone two times a day by mouth. She was then seen 
one week after the beginning of therapy. Her visual acuity was 
the same in the OD but had improved to 1/10 (20/200) in the 
OS, recognizing both letters of the Snellen chart. The ODE 
was still present in the OS. After two weeks, the visual acuity 
was the same, the ESR was 23 mm/h and the CRP was 4.8 mg/L 
(normal CRP level is less than 5 mg/L). The jaw claudication 
and left-sided temporal pain were no longer present. The ODE 
had disappeared and both optic nerves were pale. An Octopus 
VF measurement at that time showed an MD of –23.3 dB with 
a dense peripheral scotoma of 360° with a small island of cen-
tral VF. At two months, results of the ocular examination were 
the same. The patient was followed by the internist who grad-
ually reduced the steroids. Three months after treatment, the 
VF was unchanged with an MD of –22.8 dB. 
Discussion
PGE1 is a safe, potent vasodilator of the peripheral vascular sys-
tem (microcirculation or capillary system) that is used to treat 
patients with peripheral vascular disease such as intermittent 
claudication and peripheral diabetic ulcers (5,6). A  two-day 
IV treatment with PGE1 causes a vasodilation of the capillary 
system that can last for four weeks or longer in patients with 
peripheral vascular disease (7). It is well tolerated with few side 
effects, and can be used in patients who are hypotensive. It is 
important to monitor the systemic blood pressure frequently 
(every 15 min to 20 min) during its IV administration (5-7). 
The main mechanism of action of PGE1 is a vasodilation of 
the microcirculation (capillary system). PGE1 has a direct 
action on the smooth muscle of the vascular wall, leading to 
vascular dilation and increased flow. PGE1 is also known to 
inhibit platelet aggregation. PGE1 is rapidly metabolized by 
oxidation during passage through the pulmonary circulation. 
It is excreted in the urine as metabolites within approximately 
24 h (8). This rapid elimination also contributes to its safety.
AAION is a granulomatous vasculitis of the vessel walls of 
the posterior ciliary arteries and/or ophthalmic artery, and ther-
apy is immediate high-dose IV steroids, especially to protect 
against vision loss in the other eye (1). Two published studies 
(9,10) reported visual acuity improvement in patients with 
AAION using IV steroid therapy. In the first study (9), the vis-
ual acuity improved in 7% of 41 consecutive patients treated 
with IV steroid therapy. In the second study (10), the visual acu-
ity improved in 13% of 39 consecutive patients. In the two cases 
treated with IV steroids and PGE1 reported in the present article, 
there was visual acuity improvement in both. Normally, high-
dose steroids are given immediately, but the internist elected to 
use low doses in these two cases because of the presence of dia-
betes in both patients. High-dose steroids would have made 
diabetic management difficult and the patients here immediately 
responded well to the low-dose steroids together with the PGE1. 
In the current study, we used IV steroids for an additional 
two reasons. The first was that ODE was present due to swelling 
of the axons caused by axoplasmis flow stasis. Swollen axons in a 
restricted space in the opening of Bruch’s membrane and the 
scleral ring in the ONH can compress the capillaries between 
the nerve fibre bundles. It is possible that increasing the blood 
flow with PGE1 in the capillaries would cause more tissue swell-
ing at the level of the ONH. We did not want further swelling in 
an already congested area with the risk of further damage to the 
nerve fibres, and believed that IV steroids may help reduce this 
swelling and risk. The second reason for the use of IV steroids 
was to try to reduce ischemia-reperfusion (I-R) injury. The 
immediate reinstitution of blood is necessary to prevent further 
tissue damage, but the reperfusion itself may cause further tissue 
damage (ie, reperfusion injury). Infiltrating leukocytes are 
believed to play a major role in I-R injury and was one of the 
reasons we used IV steroids before the use of IV PGE1 (11,12). 
Steroids were continued orally after PGE1 because of the granu-
lomatous vasculitis and potential for I-R injury in the immediate 
post- treatment period. 
Because the decrease in visual acuity is due to ischemia, the 
addition of a potent vasodilator to immediately re-establish 
blood flow while the systemic steroids take effect could be 
important. PGE1 has been shown to improve ocular blood flow 
in patients with decreased ocular blood flow in the presence of 
peripheral vascular disease and diabetes (5). It has been used to 
treat acute ocular ischemia in the form of non-AAION and a 
branch retinal arterial occlusion (2,4). One IV infusion of 
PGE1 improves blood flow for up to four weeks in patients with 
peripheral vascular disease (7). For these reasons, we decided to 
add PGE1 to the treatment of AAION. In both patients, treat-
ment with PGE1 was given for only two days. The vasodilatory 
effect of two IV administrations of PGE1 probably lasted long 
enough for the systemic steroids to take effect and reduce the 
ischemia. In both patients, the systemic steroids were gradually 
reduced by the internist as the ESR and CRP decreased. A 
total of 2 mEq of potassium was added to each 250 mL IV 
infusion to avoid cardiac arrhythmias.
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These are only two cases involving the addition of PGE1 to 
the normal treatment of AAION with systemic steroids. The 
use of a potent systemic vasodilator to immediately improve 
ocular blood flow could help improve visual acuity in the 
ischemic eye while the steroids take effect. The authors nor-
mally use higher doses of steroids to treat AAION. It was only 
because of the presence of diabetes in these two cases that 
lower doses of steroids were used. The visual acuity initially 
improved and remained stable on all follow-up visits in both 
cases. The VFs were obtained only after treatment so that the 
start of PGE1 and steroid therapy would not be delayed. Despite 
the improved visual acuity, the VFs were markedly diminished, 
with only a small island of central vision remaining in the 
affected eyes of both patients. The use of PGE1 appeared to be 
effective without causing any systemic or ocular side effects, 
but larger studies are necessary to evaluate its use. 
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